BACKGROUND: @entity8671 reduces low-density lipoprotein @entity165 (LDL-C) and plasma lipoprotein-associated phospholipase A    (Lp- @entity1989   ) Some sartans partially activate @entity6864 (PPARy), possibly having a favorable effect on metabolic parameters. @entity9887 is the most potent partial PPARy activator, followed by @entity7056 , whereas @entity9885 does not hold such capacity. In an open-label randomized study, we assessed the effects of combining sartans of different PPARy- activating capacity with @entity8671 on LDL subfractions and plasma Lp-PLA    in @entity1 with mixed @entity2299 , @entity101 , and @entity5710 . METHODS: Following dietary intervention, @entity1 were allocated randomly to @entity8671 (10   mg/day) plus @entity9887 80   mg/day ( @entity138 group, n   =   52) or @entity7056 300   mg/day (RI group, n   =   48) or @entity9885 20   mg/day (RO group, n   =   51). After 6 months of treatment, changes in LDL subfraction @entity165 and plasma @entity6511 ) activity and mass were evaluated blindly. RESULTS: A total of 151 @entity1 (73 male; mean age 60 years) were included. Large LDL-C decreased in the @entity138 (-36%), RI (-39%), and RO (-41%) groups (P   <   0.001 for all vs. baseline). Small dense LDL-C decreased in the @entity138 (-67%), RI (-58%), and RO (-61%) groups (P   <   0.001 for all vs. baseline). All regimens increased LDL particle size versus baseline ( @entity138   +   1.4%, P   =   0.002; RI   +   1.0%, P   =   0.04; and RO   +   1.4%, P   =   0.001). No difference for the change of LDL subfractions and LDL size was noticed among groups. Plasma Lp-PLA    activity decreased equally in all groups ( @entity138 -38%, RI -38%, RO -43%) (P   <   0.001 for all vs. baseline). Plasma Lp-PLA    mass decreased similarly in all groups versus baseline ( @entity138 -28%, P   =   0.001; RI -32%, P   =   0.01; and RO -27%, P   =   0.001). No difference for the change of Lp-PLA    mass or activity was noticed among groups. CONCLUSIONS: The combination of @entity8671 with sartans of different PPARy-activating capacity did not differentiate alterations of LDL subfraction @entity165 and plasma @entity6511 ) activity and mass.

Combining XXXX with sartans of different @entity6864 activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A   .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia'] @entity5710 :: ('MESH:D011236', 'Disease') :: ['prediabetes'] @entity1989 :: ('CHEBI:60159', 'Chemical') :: ['PLA'] @entity138 :: ('MESH:C563738', 'Disease') :: ['RT'] @entity6511 :: ('7941', 'Gene') :: ['Lp-PLA(2'] @entity8671 :: ('MESH:C422923', 'Chemical') :: ['rosuvastatin', 'Rosuvastatin'] @entity7056 :: ('MESH:C081309', 'Chemical') :: ['irbesartan'] @entity9885 :: ('MESH:C437965', 'Chemical') :: ['olmesartan'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol'] @entity9887 :: ('MESH:C084178', 'Chemical') :: ['Telmisartan', 'telmisartan'] @entity6864 :: ('5468', 'Gene') :: ['peroxisome proliferator-activated receptor-y']
@entity8671 :: (MESH:C422923,Chemical) :: ['rosuvastatin']
